Adjuvant chemotherapy in luminal breast cancers
Authors:
- Elgene LimELElgene Lim
- Eric P. WinerEWEric P. Winer
Open Access
- 31 October 2011
- journal article
- research article
- Published by Elsevier in The Breast
- Vol. 20, S128-S131
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trialThe Lancet, 2009
- Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009Annals of Oncology, 2009
- Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor–Positive Breast Carcinomas Through Genomic GradeJournal of Clinical Oncology, 2007
- Estrogen-Regulated Genes Predict Survival in Hormone Receptor–Positive Breast CancersJournal of Clinical Oncology, 2006
- Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast CancerJAMA, 2006
- Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancerJournal of Clinical Oncology, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences, 2003
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001
- Molecular portraits of human breast tumoursNature, 2000